Rhinomed (ASX:RNO) is pleased to announce that it has entered into a working capital financing facility to the value of AUD$2 million. The facility is provided from an entity related to the company Chairman Ron Dewhurst. The facility is unsecured and can be drawn upon in multiples of $250,000. Interest is at commercial rates. The facility is repayable by 31 July 2018.
EnquiriesMichael Johnson, CEO & Director
+61 (0) 8416 0900
mjohnson@rhinomed.global
Follow us on Twitter @rhinomedceo and @theturbinecom
About Rhinomed Limited (ASX: RNO)Rhinomed Limited is a Melbourne based technology firm with a focus on nasal, respiratory and breathing management technologies. The company is seeking to monetise applications of its technology portfolio
in the Sport, Sleep, Wellbeing and Drug Delivery markets. For more information go to
www.rhinomed.global
Rhinomed Limited published this content on 30 January 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 22 February 2017 09:11:07 UTC.
Original documenthttp://www.rhinomed.global/wp-content/uploads/2017/02/Working-Capital-Facility.pdf
Public permalinkhttp://www.publicnow.com/view/7473BD7A9721E53A7C1F15DEACA43EECE9E4790B